ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ADVM Adverum Biotechnologies Inc

7.35
-0.10 (-1.34%)
08 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Adverum Biotechnologies Inc NASDAQ:ADVM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.10 -1.34% 7.35 7.17 7.94 7.49 7.27 7.40 93,793 01:00:00

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

03/05/2024 1:00pm

GlobeNewswire Inc.


Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart


From Apr 2024 to Jun 2024

Click Here for more Adverum Biotechnologies Charts.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming investor conferences:

  • 2024 RBC Global Healthcare Conference on Tuesday, May 14, 2024 at 4:05 p.m. ET.
  • BofA Securities 2024 Health Care Conference on Wednesday, May 16, 2024 at 3:40 p.m. PT.
  • H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024 at 11:00 a.m. ET.

The on-demand webcast of the panel discussion may be accessed under Events and Presentations in the Investors section of Adverum’s website. A replay of the webcast will be available on the website for at least 30 days following the presentation.

About Adverum Biotechnologies

Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.

Inquiries:

Adverum Investor Relations

Email: ir@adverum.com

1 Year Adverum Biotechnologies Chart

1 Year Adverum Biotechnologies Chart

1 Month Adverum Biotechnologies Chart

1 Month Adverum Biotechnologies Chart

Your Recent History

Delayed Upgrade Clock